Stock OSE OSE IMMUNOTHERAPEUTICS
Add to a list
To use this feature you must be a member
Log inSign up

All News OSE Immunotherapeutics

Equities

OSE

FR0012127173

Real-time Euronext Paris
Other stock markets
 09:26:49 2024-06-27 EDT 		5-day change 1st Jan Change
5.87 EUR -2.98% Intraday chart for OSE Immunotherapeutics -6.97% +37.15%
06-24 OSE: market welcomes CAR-T agreement CF
06-24 OSE Immunotherapeutics SA Enters into a Commercial and Revenue Sharing Agreement with Memorial Sloan Kettering Cancer Center CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
OSE: market welcomes CAR-T agreement
CF
OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies
GL
OSE Immunotherapeutics SA Enters into a Commercial and Revenue Sharing Agreement with Memorial Sloan Kettering Cancer Center
CI
OSE: treatment prospects with therapeutic mRNA
CF
OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders at the FOCIS Annual Meeting, San Francisco (June 18 – 21)
GL
OSE Immunotherapeutics Presents Preclinical Data on Mrna Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders At the Focis Annual Meeting, San Francisco
CI
OSE Immunotherapeutics : Reports on its 2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company’s Growth
PU
OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company’s Growth
GL
OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancer by Dr Stephen Liu and Prof Benjamin Besse
GL
Transcript : OSE Immunotherapeutics SA - Special Call
OSE Immuno: positive analysis presented at ATC congress
CF
OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant
GL
OSE Immuno: towards an evolution of the Board of Directors
CF
OSE Immunotherapeutics Provides Business and Corporate Update
GL
OSE Immuno: up on analysts' comments
CF
Invest Securities Lifts OSE Immuno PT, Maintains at Buy
MT
OSE IMMUNO : Invest Securities raises its target
CF
OSE, Boehringer Ingelheim Expand Partnership for Immuno-oncology Programs
MT
OSE: agreement extended with Boehringer Ingelheim, share price rises
CF
OSE Immunotherapeutics : and Boehringer Ingelheim expand collaboration to develop first in class treatments for cancer and cardio renal metabolic diseases
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OSE Stock
  4. News OSE Immunotherapeutics